“We are impressed with the successful study outcomes and performance of Galen Breast, which were in near perfect concordance with the consensus diagnosis between pathologists in distinguishing between malignant and benign biopsies, and between invasive and in-situ carcinoma and other histological types,” said Anne Vincent-Salomon, MD, Director of Pathology at Institut Curie and the principal investigator in the study. “Our team demonstrated that Ibex’s AI technology goes beyond detecting cancer and provides accurate insights on the type of tumor, the nuclear grading of in situ carcinomas and more. I’m confident that artificial intelligence will support breast pathologists and provide benefit to cancer patients across multiple segments of the diagnostic workflow and look forward to seeing this technology widely adopted in the field.”
“In this age of personalized medicine, getting the most accurate and most precise diagnosis in breast pathology is more important than ever. We look forward to innovative technologies that could offer actionable insights in support of quality diagnosis,” said Stuart Schnitt, MD, Chief of Breast Oncologic Pathology at the Dana-Farber/Brigham and Women's Cancer Center and Professor of Pathology at Harvard Medical School. “AI has already demonstrated its immense value in helping pathologists improve the quality and efficiency of prostate cancer diagnosis. The outcomes of this breast study strongly demonstrate that Ibex’s technology is well positioned to make similar impact on breast cancer diagnosis.”
Ad Statistics
Times Displayed: 120835
Times Visited: 6950 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
“We are proud to have obtained this milestone CE Mark for our Galen Breast solution” said Daphna Laifenfeld, PhD, Chief Scientific Officer at Ibex Medical Analytics, “The excellent results coming out of this study demonstrate the robustness of our Strong AI technology and enable us to offer pathologists an unprecedented breadth of features. We have secured multiple orders for Galen Breast from leading health systems in Europe, and we look forward to accelerating its deployment in the very near future.”
Back to HCB News
